Immunogenicity and protective efficacy of Middle East respiratory syndrome coronavirus virus-like particles in mouse model Jung-Eun Park1, Hyun Jang2, Hyun-Jin Shin1 1Chungnam National University, Daejeon, Republic of Korea 2Woogene B&G Co. Ltd, Yesan, Republic of Korea
Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe respiratory diseases in human with a mortality of 40%. No antiviral therapies or vaccines are available for its treatment or prophylaxis. Here, we evaluated the utility of MERS-CoV virus-like particles (VLPs) for MERS-CoV vaccine development. MERS-CoV VLPs expressed viral structural proteins that resemble MERS-CoV. Using a human DPP4 knock-in lethal mouse model, we showed that intramuscular immunization with MERS-CoV VLPs is highly immunogenic and confers protection against lethal viral challenge. These data provide that MERS-CoV VLPs are the promising candidate for MERS-CoV vaccine in humans and dromedary camels.
Credits: None available.
You must be logged in and own this product in order to post comments.